NEW YORK (TheStreet) -- On CNBC's "Cramer's Stop Trading" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said trading on the last day of the quarter can be tough, since fund managers are doing a lot of juggling with their positions.
The results, which can also be helpful in treating asthma and atopic dermatitis, should have shares of Regeneron higher by $10. However, since the overall biotech sector is lower due to it being the last day of the quarter, the stock is not reacting the same, Cramer reasoned.
Investors shouldn't "freak out" because of the price action. It will be fine once the fourth quarter begins. Cramer said he expects the stock market to be strong next quarter, as more money continues to come into U.S. equities.
-- Written by Bret Kenwell in Petoskey, Mich.